Rigaku Collaborates on X-ray Analysis of Fusuma-e by Maruyama Okyo
Article content
TOKYO — Rigaku Corporation, a global solution partner in X-ray analytical devices and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter 'Rigaku') has conducted measurements of fusuma-e in Daijoji, a temple in Mikata-gun, Hyogo Prefecture. Fusuma-e, also called shohekiga, are images drawn on fusuma, traditional sliding partitions.
Article content
Article content
The measurements were conducted as part of a research project to 'restore the original colors of the gold-leaf backing of fusuma-e drawn by Maruyama Okyo (1733–1795), a painter of the mid to late Edo period. The project is being conducted through the collaboration of three researchers: Shinno Yamasoba, assistant chief priest of Daijoji Temple and project leader; Tetsuya Senda, formerly of the National Maritime Research Institute; and Takeshi Tanaka, artist and professor at Tohoku University of Art & Design.
Article content
The purpose of the measurements was to investigate scientifically the artistic intention of Maruyama Okyo, the historical context in which he painted, and the impact that restoration would have. The team used the Thermo Scientific™ Niton™ XL5 Plus, a handheld X-ray fluorescence (XRF) analyzer, for its ability to analyze material composition non-destructively. Detailed data were acquired, focusing on the following three areas of interest.
Article content
The team measured to determine whether the gold foil used in the two center panels and the two end panels were of the same or different composition. Confirmation that the compositions are different would provide scientific evidence that the fusuma-e were produced at different times.
Article content
Preliminary measurements suggest that gold foil was used on panels with colored drawings of basho (Japanese fiber banana) to produce a bright, reddish tinge, and on panels with ink drawings of peacocks to create a dark, bluish aspect. In this measurement, the compositions of all fusuma were analyzed to examine further whether different color gradations of gold foil were used in two-panel spaces to create perspective (sense of depth). The results are expected to lead to fresh understanding of the expressive techniques of Okyo.
Article content
The team compared the gold foil Okyo used in the original paintings in the Edo era with the gold foil used in repairs in the early Meiji era (mid-to-late 19 th century). This measurement was a precious opportunity to obtain quantitative data on the gold foil used in the Edo era.
Article content
These analytical results are expected to be used as a scientific resource to deepen understanding of the painting aches and techniques of Maruyama Okyo.
Article content
Rigaku will continue to contribute to the preservation of cultural treasures and transmission of them to future generations through science and technology.
Article content
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations 'To Improve Our World by Powering New Perspectives.'
For details, please visit rigaku-holdings.com/english
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
a day ago
- National Post
Blue Planet Prize 2025: Announcement of Prize Laureates
Article content TOKYO — This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates. Article content 1. Professor Robert B. Jackson (USA) Born on September 26, 1961 Department of Earth System Science, Stanford University Article content Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions. Article content 2. Dr. Jeremy Leggett (UK) Born on March 16, 1954 Founder and CEO of Highlands Rewilding Ltd. Inaugural chairman of the Carbon Tracker Initiative Article content Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the 'carbon bubble,' highlighting the economic risks associated with fossil fuel assets. Through CTI's activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK's leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity. Article content Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money. The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively. Article content Article content Article content Article content Article content Contacts Article content
National Post
2 days ago
- National Post
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
Article content EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure Article content NEUCHATEL, Switzerland — Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine ® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery. 1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation anesthetic (sevoflurane) needed to maintain anesthesia in pediatric patients, reducing their exposure to the drug. In turn, the patients experienced a significantly lower rate of pediatric anesthesia emergence delirium, or PAED, which commonly manifests in confusion, agitation, or hallucinations experienced during recovery. When compared with standard practice, children monitored with SedLine also regained consciousness faster and could be safely discharged to the post-anesthesia care unit, or PACU, sooner – time savings that, the researchers noted, may represent additional cost savings. In sum, the researchers found that Masimo SedLine helped to make pediatric anesthesia safer, more efficient, and more cost effective. Article content In sum, the researchers found that Masimo SedLine helped to make pediatric anesthesia safer, more efficient, and more cost effective. Article content Children monitored with SedLine were exposed to an average of 1.4 MAC hours less sevoflurane and had a 14% lower incidence rate of PAED. On average, they regained consciousness 53% sooner and were discharged from the PACU 48% sooner. The time saved led to an estimated cost savings of $240 to $920 per patient. Article content PAED is a frequent and clinically significant complication in pediatric anesthesia, 2 often leading to short-term distress among pediatric patients, parents, and staff. Some of the negative postoperative behaviors can persist for weeks or months. 3 Exposure to commonly used volatile anesthetics like sevoflurane gas has been shown to contribute to PAED. 4 In current standard practice, a fixed amount of sevoflurane, 1.0 minimum alveolar concentration (MAC), is used to maintain pediatric anesthesia, but as the authors note, that may be excessive. 5 Dr. Nagasaka and her team hypothesized that by using bilateral EEG – in particular, the waveforms and multitaper density spectral array (DSA) spectrograms displayed by Masimo SedLine – to guide sevoflurane titration, the amount needed to induce and maintain appropriate sedation could be reduced, thereby reducing the incidence of PAED. Article content In the study, children aged 1 to 6 years scheduled for elective surgery involving at least 30 minutes of general anesthesia at the largest children's hospital in Japan were randomly assigned to an experimental group (n=91), whose anesthesia was guided by Masimo SedLine, or a control group (n=86), whose anesthesia was guided using standard practice, i.e. a fixed sevoflurane dosage of 1.0 MAC. The researchers recorded the amount of sevoflurane exposure for each patient and the time elapsed between important events including intubation, extubation, arrival and discharge from the PACU, and emergence from anesthesia. All patients were assessed for PAED by clinicians blinded to the treatment assignment, using a standard scale. Article content The researchers found that the incidence of PAED was significantly lower among patients in the SedLine group, affecting 21% of patients vs. 35% of patients in the control group (p=0.04). SedLine group patients were exposed to significantly less sevoflurane, by an average 1.4 MAC hours. They were extubated sooner, by an average of 3.3 minutes, regained consciousness sooner, by an average of 21.4 minutes, and were discharged from the PACU sooner, by an average of 16.5 minutes. The researchers estimated that the reduction in time spent in the OR and PACU, of approximately 20 minutes, may represent a cost savings of $240 to $920 (USD) per case. Article content The authors concluded, 'EEG-guided management of general anesthesia reduced sevoflurane exposure and pediatric anesthesia emergence delirium in children, with faster emergence and shorter post-anesthesia care unit stays. The findings suggest that high concentrations of sevoflurane for induction followed by routine use of 1.0-MAC sevoflurane for maintenance may be excessive.' Article content They also noted that 'with EEG monitoring, parents and guardians may be reassured that health care professionals can make an active effort to reduce and minimize a child's exposure to anesthetic drugs.' Article content A similar study in 2022 by Long et al. – one of the first to investigate the impact of EEG-guided anesthesia on children undergoing surgery – found that pediatric patients monitored with SedLine experienced significantly fewer EEG patterns of profound brain inactivity, known as burst suppression. Burst Suppression has also been associated with adverse outcomes, including postoperative delirium. 6 Yasuko Nagasaka, Professor of Anesthesia at Tokyo Women's Medical University and the new study's senior author, commented, 'While general anesthesia is necessary for pediatric patients undergoing surgery, parents and guardians may express concerns about their child's exposure to anesthetic drugs. We can now offer reassurance by explaining that modern medical technologies, such as EEG-guided anesthesia care, help minimize anesthetic exposure, potentially reducing the incidence of pediatric emergence delirium (PAED) and supporting earlier awakening and recovery from unconsciousness.' Article content 'It is important to recognize,' continued Dr. Nagasaka, 'that increasing the depth of anesthesia is relatively easy to learn. On the other hand, developing the confidence and skill to safely reduce anesthesia requires deeper understanding. Our results may offer a great step forward towards the improvement of our common practice, which may lead to the development of guidelines for EEG monitoring in pediatric areas to eventually mandate EEG monitoring during general anesthesia in the future. But comprehensive training in EEG-guided anesthesia should be considered a critical next step for the entire anesthesia community.' Article content Dean Kurth, MD, attending anesthesiologist at Children's Hospital of Philadelphia and Professor of Anesthesiology and Critical Care Medicine at the University of Pennsylvania Perelman School of Medicine, added, 'This study by Miyasaka et al. confirms the growing realization by pediatric anesthesiologists worldwide that more anesthesia drug is being administered to children than necessary, which has negative consequences. As the authors have shown, SedLine EEG data can help clinicians provide more precise anesthetic drug dosing for each child and improves outcomes.' Article content References Article content Miyasaka K, Suzuki Y, Brown E, Nagasaka Y. EEG-Guided Titration of Sevoflurane and Pediatric Anesthesia Emergence Delirium. JAMA Pediatrics. April 21, 2025. DOI: 10.1001/jamapediatrics.2025.0517. Cole JW, Murray DJ, McAllister JD, Hirshberg GE. Emergence behavior in children: defining the incidence of excitement and agitation following anaesthesia. Paediatr Anaesth. 2002;12(5):442-447. DOI:10.1046/j.1460-9592.2002.00868.x. Davis L, Qi TS, and Ng A. Emergence delirium: an overview with an emphasis on the use of electroencephalography in its management. Anest Pain Med. 2024;19(Suppl 1):S87-95. DOI: 10.17085/apm.24013. Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. Br J Anaesth. 2017;118(3):335-343. DOI: 10.1093/bja/aew477. Goddard N, Smith D. Unintended awareness and monitoring of depth of anaesthesia. Contin Educ Anaesth Crit Care Pain. 2013;13(6):213-217. Long MHY, Lim EHL, Balanza GA, Allen JC, Purdon PL, and Bong CL. Sevoflurane requirements during electroencephalogram (EEG)-guided vs. standard anesthesia care in children: A randomized controlled trial. J Clin Anesth. 27 Jun 2022. DOI: Article content About Masimo Article content Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at Masimo SET ® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at Forward-Looking Statements Article content This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding the performance of SedLine to achieve certain results including the incidence of pediatric emergence delirium, earlier awakening, recovery from unconsciousness, or cost savings; the rate of adoption of SedLine technology by pediatric anesthesiologists for use during anesthesia administration in children undergoing surgery; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'on-going,' 'opportunity,' 'plan,' 'potential,' 'predicts,' 'forecast,' 'project,' 'seek,' 'should,' 'will,' or 'would,' the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: the highly competitive nature of the markets in which we sell our products and technologies; the ability to obtain regulatory approvals; the lack of acceptance of any of our current or future products and technologies; and other factors discussed in the 'Risk Factors' section of our most recent periodic reports filed with the Securities and Exchange Commission ('SEC'), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the 'Risk Factors' contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws. Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Masimo Article content Article content Article content Article content
National Post
3 days ago
- National Post
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
Article content VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. Article content SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. Article content Article content 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' Article content 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' Article content About SOLVE FSHD Article content SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Article content Article content Article content Article content Contacts Article content
